A Study to Evaluate the Efficacy and Safety of Apremilast in Patients of Chronic and Recurrent Erythema Nodosum Leprosum

Clinical Trial ID NCT04822909

Rank	Title	Journal	Year	PubWeight™‹?›
1	Classification of leprosy according to immunity. A five-group system.	Int J Lepr Other Mycobact Dis	1966	22.28
2	Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.	Lancet	2012	2.34
3	Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.	Br J Pharmacol	2009	1.89
4	Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis.	J Rheumatol	2015	1.07
5	Comparing the clinical and histological diagnosis of leprosy and leprosy reactions in the INFIR cohort of Indian patients with multibacillary leprosy.	PLoS Negl Trop Dis	2012	0.94
6	Interventions for erythema nodosum leprosum.	Cochrane Database Syst Rev	2009	0.88
7	IgG antibody subclasses, tumor necrosis factor and IFN-gamma levels in patients with type II lepra reaction on thalidomide treatment.	Int Arch Allergy Immunol	1998	0.82
8	Classification of leprosy into multibacillary and paucibacillary groups: an analysis.	FEMS Immunol Med Microbiol	2008	0.78
9	Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2).	J Am Acad Dermatol	2017	0.75
10	A leprosy clinical severity scale for erythema nodosum leprosum: An international, multicentre validation study of the ENLIST ENL Severity Scale.	PLoS Negl Trop Dis	2017	0.75